Revolution Medicines D
RVMD
Revolution Medicines return on equity (ROE)What is return on equity (ROE)? Return on equity (ROE) is a year of net income divided by shareholders' equity: the profit a company makes on each dollar its owners have in it.
Revolution Medicines's return on equity is -77.89%: net income of -1.87B USD over the last twelve months on shareholders' equity of 2.40B USD.
- Today
- -77.89%
- Average, 5 years
- -43.76%
- Low, 5 years
- -91.45%
- High, 5 years
- -23.89%
ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = -1.87B ÷ 2.40B = -77.89%
Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.
What drives Revolution Medicines's return on equity?What is DuPont analysis? DuPont analysis splits return on equity into three parts: profit margin, asset turnover and the equity multiplier. It shows whether a high ROE comes from profits, from using assets well, or from debt.
- FY2023-3,768.3% × 0.01 × 1.13 = -23.9%
- FY2022-703.0% × 0.04 × 1.18 = -36.3%
- FY2021-636.6% × 0.04 × 1.22 = -31.0%
- FY2020-251.6% × 0.08 × 1.20 = -22.8%
- FY2019-95.2% × 0.23 × 1.45 = -31.2%
The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.
ROE (return on equity) by year and by quarter
| Fiscal year | Period ending | ROE (return on equity) | Net income | Shareholders' equity |
|---|---|---|---|---|
| Today | -77.89% | -1.87B | 2.40B | |
| FY2025 | 31 Dec 2025 | -69.35% | -1.13B | 1.63B |
| FY2024 | 31 Dec 2024 | -26.49% | -600.09M | 2.27B |
| FY2023 | 31 Dec 2023 | -23.89% | -436.37M | 1.83B |
| FY2022 | 31 Dec 2022 | -36.30% | -248.71M | 685.19M |
| FY2021 | 31 Dec 2021 | -31.05% | -187.09M | 602.57M |
| FY2020 | 31 Dec 2020 | -22.79% | -108.16M | 474.68M |
| FY2019 | 31 Dec 2019 | -31.25% | -47.66M | 152.54M |
| FY2018 | 31 Dec 2018 | -43.23% | -41.79M | 96.66M |
| FY2017 | 31 Dec 2017 | -686.98% | -31.13M | 4.53M |
| Quarter | Period ending | ROE (return on equity) | Net income | Shareholders' equity |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | -77.89% | -1.87B | 2.40B |
| Q2 FY2026 | 30 Jun 2026 | -67.85% | -1.77B | 2.61B |
| Q1 FY2026 | 31 Mar 2026 | -91.45% | -1.37B | 1.50B |
| Q4 FY2025 | 31 Dec 2025 | -69.35% | -1.13B | 1.63B |
| Q3 FY2025 | 30 Sept 2025 | -60.18% | -960.98M | 1.60B |
| Q2 FY2025 | 30 Jun 2025 | -43.53% | -812.06M | 1.87B |
| Q1 FY2025 | 31 Mar 2025 | -33.56% | -697.51M | 2.08B |
| Q4 FY2024 | 31 Dec 2024 | -26.49% | -600.09M | 2.27B |
| Q3 FY2024 | 30 Sept 2024 | -36.20% | -567.06M | 1.57B |
| Q2 FY2024 | 30 Jun 2024 | -32.07% | -519.21M | 1.62B |
| Q1 FY2024 | 31 Mar 2024 | -28.07% | -484.27M | 1.73B |
| Q4 FY2023 | 31 Dec 2023 | -23.89% | -436.37M | 1.83B |
| Q3 FY2023 | 30 Sept 2023 | -39.56% | -331.34M | 837.46M |
| Q2 FY2023 | 30 Jun 2023 | -31.82% | -296.23M | 930.84M |
| Q1 FY2023 | 31 Mar 2023 | -27.22% | -259.16M | 952.22M |
| Q4 FY2022 | 31 Dec 2022 | -36.30% | -248.71M | 685.19M |
| Q3 FY2022 | 30 Sept 2022 | -35.94% | -244.87M | 681.42M |
| Q2 FY2022 | 30 Jun 2022 | -45.00% | -224.49M | 498.84M |
| Q1 FY2022 | 31 Mar 2022 | -37.67% | -207.56M | 550.99M |
| Q4 FY2021 | 31 Dec 2021 | -31.05% | -187.09M | 602.57M |
| Q3 FY2021 | 30 Sept 2021 | -26.42% | -168.62M | 638.20M |
| Q2 FY2021 | 30 Jun 2021 | -20.86% | -142.90M | 685.01M |
| Q1 FY2021 | 31 Mar 2021 | -17.41% | -125.82M | 722.58M |
| Q4 FY2020 | 31 Dec 2020 | -22.79% | -108.16M | 474.68M |
| Q3 FY2020 | 30 Sept 2020 | -17.53% | -88.55M | 505.07M |
| Q2 FY2020 | 30 Jun 2020 | -20.57% | -74.15M | 360.50M |
| Q1 FY2020 | 31 Mar 2020 | -14.81% | -57.05M | 385.32M |
| Q4 FY2019 | 31 Dec 2019 | -31.25% | -47.66M | 152.54M |
| Q3 FY2019 | 30 Sept 2019 | -26.80% | -44.41M | 165.67M |
| Q2 FY2019 | 30 Jun 2019 | — | — | — |
| Q1 FY2019 | 31 Mar 2019 | — | — | 96.66M |
| Q4 FY2018 | 31 Dec 2018 | — | — | 96.66M |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:Market cap,Debt to equity,Current ratio,All ratios
Common questions about Revolution Medicines's ROE
Source: Financial Modeling PrepVerified against SEC filings